Key Highlights
- Shares of Travere Therapeutics (TVTX) climbed 44% following FDA clearance of FILSPARI for treating FSGS
- FILSPARI represents the inaugural FDA-sanctioned therapy for focal segmental glomerulosclerosis
- The treatment is indicated for patients 8 years and older who don’t exhibit nephrotic syndrome
- Over 30,000 U.S. patients could potentially benefit from this newly approved medication
- Guggenheim analysts lifted their TVTX price objective to $54 from $49 while reaffirming their Buy stance
Shares of Travere Therapeutics (TVTX) skyrocketed 44% during Tuesday’s session after federal regulators authorized FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis—a rare kidney disorder that previously lacked any approved therapeutic options.
Travere Therapeutics, Inc., TVTX
The regulatory clearance applies to patients aged 8 years and above diagnosed with FSGS who aren’t experiencing nephrotic syndrome. FILSPARI now stands as the pioneering FDA-sanctioned medication specifically for FSGS treatment.
This milestone represents FILSPARI’s second approved indication for rare kidney disorders, adding to its existing authorization for IgA nephropathy treatment.
According to Travere’s estimates, more than 30,000 FSGS patients in the United States qualify for treatment under the approved criteria—specifically those who don’t present with the three simultaneous indicators of nephrotic syndrome.
Clinical Trial Results
The regulatory approval stemmed from results of the Phase 3 DUPLEX Study, characterized as the most extensive interventional clinical trial conducted for FSGS to date.
Patients receiving FILSPARI demonstrated a 46% decline in proteinuria levels from their starting point through Week 108. By comparison, participants taking the control medication—maximum-dosage irbesartan—experienced only a 30% reduction.
Among the subset of participants without nephrotic syndrome, FILSPARI achieved an even more impressive 48% proteinuria decrease compared to just 27% for irbesartan.
Additionally, FILSPARI-treated patients within this subgroup exhibited favorable eGFR outcomes, showing a treatment advantage of 1.1 mL/min/1.73 m² at the 108-week mark.
The medication demonstrated a safety profile essentially equivalent to irbesartan in both adult and pediatric patient populations—a critical finding that should facilitate commercial adoption.
Wall Street Response
Guggenheim’s analyst Vamil Divan elevated his TVTX price target to $54 from a previous $49 while maintaining a Buy recommendation in response to the announcement.
Divan indicated the final approved label exceeded expectations, highlighting that the eligible patient population proved broader than market consensus had anticipated.
The label specifically encompasses both primary and secondary forms of FSGS—extending beyond merely the primary and genetic variants that analysts and company leadership had previously modeled as the core addressable market.
This expanded coverage creates a significantly larger commercial opportunity than many investors had factored into their valuations.
TipRanks reports an additional analyst Buy recommendation with a $47 price objective for the shares, while rating the technical sentiment indicator as a Buy.
Following Tuesday’s dramatic advance, TVTX’s market capitalization stands at roughly $2.67 billion.
The FDA authorization was disclosed on April 13, 2026, with the stock’s surge occurring throughout Tuesday’s trading hours.
The post Travere Therapeutics (TVTX) Stock Rockets 44% on Groundbreaking FSGS Treatment Approval appeared first on Blockonomi.